Literature DB >> 26072071

Inhibitory effects of parthenolide on the activity of NF-κB in multiple myeloma via targeting TRAF6.

Fan-Cong Kong1, Jing-Qiong Zhang2, Chen Zeng1, Wen-Lan Chen1, Wen-Xiang Ren1, Guo-Xin Yan1, Hong-Xiang Wang3, Qiu-Bai Li4, Zhi-Chao Chen5.   

Abstract

This study examined the mechanism of the inhibitory effect of parthenolide (PTL) on the activity of NF-κB in multiple myeloma (MM). Human multiple myeloma cell line RPMI 8226 cells were treated with or without different concentrations of PTL for various time periods, and then MTT assay was used to detect cell proliferation. Cell cycle and apoptosis were flow cytometrically detected. The level of protein ubiquitination was determined by using immunoprecipitation. Western blotting was employed to measure the level of total protein ubiquitination, the expression of IκB-α in cell plasma and the content of p65 in nucleus. The content of p65 in nucleus before and after PTL treatment was also examined with immunofluorescence. Exposure of RPMI 8226 cells to PTL attenuated the level of ubiquitinated Nemo, increased the expression of IκB-α and reduced the level of p65 in nucleus, finally leading to the decrease of the activity of NF-κB. PTL inhibited cell proliferation, induced apoptosis and blocked cell cycle. Furthermore, the levels of ubiquitinated tumor necrosis factor receptor-associated factor 6 (TRAF6) and total proteins were decreased after PTL treatment. By using Autodock software package, we predicted that PTL could bind to TRAF6 directly and tightly. Taken together, our findings suggest that PTL inhibits the activation of NF-κB signaling pathway via directly binding with TRAF6, thereby suppressing MM cell proliferation and inducing apoptosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26072071     DOI: 10.1007/s11596-015-1435-0

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  24 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma.

Authors:  Ellen J Gunn; John T Williams; Daniel T Huynh; Michael J Iannotti; Changho Han; Francis J Barrios; Stephen Kendall; Carlotta A Glackin; David A Colby; Julia Kirshner
Journal:  Leuk Lymphoma       Date:  2011-03-21

3.  Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation.

Authors:  Betty Lamothe; Arnaud Besse; Alejandro D Campos; William K Webster; Hao Wu; Bryant G Darnay
Journal:  J Biol Chem       Date:  2006-11-29       Impact factor: 5.157

4.  Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells.

Authors:  Siyuan Zhang; Zhong-Ning Lin; Cheng-Feng Yang; Xianglin Shi; Choon-Nam Ong; Han-Ming Shen
Journal:  Carcinogenesis       Date:  2004-07-15       Impact factor: 4.944

Review 5.  Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma.

Authors:  Ota Fuchs
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2013-03-01

6.  An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

Authors:  Monica L Guzman; Randall M Rossi; Sundar Neelakantan; Xiaojie Li; Cheryl A Corbett; Duane C Hassane; Michael W Becker; John M Bennett; Edmund Sullivan; Joshua L Lachowicz; Andrew Vaughan; Christopher J Sweeney; William Matthews; Martin Carroll; Jane L Liesveld; Peter A Crooks; Craig T Jordan
Journal:  Blood       Date:  2007-09-05       Impact factor: 22.113

7.  Inhibitory effects of parthenolide on the angiogenesis induced by human multiple myeloma cells and the mechanism.

Authors:  Fancong Kong; Zhichao Chen; Qiubai Li; Xiaolong Tian; Juan Zhao; Ke Yu; Yong You; Ping Zou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-10-10

8.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

9.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Authors:  Christina M Annunziata; R Eric Davis; Yulia Demchenko; William Bellamy; Ana Gabrea; Fenghuang Zhan; Georg Lenz; Ichiro Hanamura; George Wright; Wenming Xiao; Sandeep Dave; Elaine M Hurt; Bruce Tan; Hong Zhao; Owen Stephens; Madhumita Santra; David R Williams; Lenny Dang; Bart Barlogie; John D Shaughnessy; W Michael Kuehl; Louis M Staudt
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

10.  TRAF6-deficient mice display hypohidrotic ectodermal dysplasia.

Authors:  Asuka Naito; Hisahiro Yoshida; Eri Nishioka; Mizuho Satoh; Sakura Azuma; Tadashi Yamamoto; Shin-ichi Nishikawa; Jun-ichiro Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

View more
  9 in total

1.  Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth.

Authors:  Xue Li; Lingmei Kong; Qihong Yang; Aizhu Duan; Xiaoman Ju; Bicheng Cai; Lin Chen; Tao An; Yan Li
Journal:  J Biol Chem       Date:  2020-02-06       Impact factor: 5.157

2.  Parthenolide Inhibits Angiogenesis in Esophageal Squamous Cell Carcinoma Through Suppression of VEGF.

Authors:  Bo Tian; Yuhang Xiao; Junliang Ma; Wei Ou; Hui Wang; Jie Wu; Jinming Tang; Baihua Zhang; Xiaojuan Liao; Desong Yang; Zhining Wu; Xu Li; Yong Zhou; Min Su; Wenxiang Wang
Journal:  Onco Targets Ther       Date:  2020-07-29       Impact factor: 4.147

3.  Synergy between parthenolide and arsenic trioxide in adult T-cell leukemia/lymphoma cells in vitro.

Authors:  Hamideh Kouhpaikar; Mohammad Hadi Sadeghian; Houshang Rafatpanah; Mohaddeseh Kazemi; Mehrdad Iranshahi; Zahra Delbari; Faezeh Khodadadi; Hossein Ayatollahi; Fatemeh B Rassouli
Journal:  Iran J Basic Med Sci       Date:  2020-05       Impact factor: 2.699

4.  Anti-rheumatic drug iguratimod (T-614) alleviates cancer-induced bone destruction via down-regulating interleukin-6 production in a nuclear factor-κB-dependent manner.

Authors:  Yue Sun; Da-Wei Ye; Peng Zhang; Ying-Xing Wu; Bang-Yan Wang; Guang Peng; Shi-Ying Yu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

5.  An in vitro study on the effects of the combination of salinomycin with cisplatin on human gastric cancer cells.

Authors:  Zuwen Zhang; Jumei Zhao; Qiuxia Pang; Aihong Wang; Meini Chen; Xiaoli Wei
Journal:  Mol Med Rep       Date:  2017-06-08       Impact factor: 2.952

6.  Effects of salinomycin and 17‑AAG on proliferation of human gastric cancer cells in vitro.

Authors:  Zuwen Zhang; Jumei Zhao; Zhikuan Mi; Qiuxia Pang; Aihong Wang; Meini Chen; Xiaobin Liu; Xiaoli Wei; Tao Liu
Journal:  Mol Med Rep       Date:  2017-06-09       Impact factor: 2.952

7.  Natural Compounds As Modulators of Non-apoptotic Cell Death in Cancer Cells.

Authors:  Luis Miguel Guamán-Ortiz; Maria Isabel Ramirez Orellana; Edward A Ratovitski
Journal:  Curr Genomics       Date:  2017-04       Impact factor: 2.236

Review 8.  The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy.

Authors:  Tao An; Huanhuan Yin; Yanting Lu; Feng Liu
Journal:  Drug Des Devel Ther       Date:  2022-04-29       Impact factor: 4.319

Review 9.  TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis.

Authors:  Nikolay N Kuzmich; Konstantin V Sivak; Vladimir N Chubarev; Yuri B Porozov; Tatiana N Savateeva-Lyubimova; Francesco Peri
Journal:  Vaccines (Basel)       Date:  2017-10-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.